Mean (standard deviation) age was 49.4 (9.0) years; 14 patients were men, and 13 patients (37.1%) had aspirin-exacerbated respiratory disease (42.1% placebo, 31.3% dupilumab). At baseline, patients had moderate-to-severe CRSwNP, and inflammatory biomarker levels were generally similar across treatment groups. Among patients with CRSwNP and comorbid asthma, dupilumab-treated patients (vs placebo) showed a significant improvement in endoscopic NP score (P < .001), sense of smell (P < .001), Lund-Mackay computed tomography total score (P < .001), and significant reduction in CRSwNP disease severity (P < .001). Furthermore, a significant improvement in the total 22-item Sino-Nasal Outcome Test score at week 16 was observed in dupilumab-treated patients (vs placebo) (P < .001). Dupilumab versus placebo also produced significant improvements in forced expiratory volume in 1 second % predicted (P ¼ .04) and 5-item Asthma Control Questionnaire (ACQ-5) total score (P < .001) exceeding the minimal clinically important difference (MCID) of 0. 5. 7 In this study, we further assessed the effect of dupilumab on HRQoL in patients with CRSwNP with comorbid asthma using the 5-dimension EuroQoL questionnaire (EQ-5D) visual analog scale (VAS) and 36-item Short-Form Health Survey (SF-36). EQ-5D VAS provides a simple measure of the patient's self-rated health on a vertical virtual analog scale, with scores 0 to 100 mm (worst-best imaginable health state).
8 SF-36 comprises 8 domains assessing physical functioning, social functioning, role limitations due to physical and emotional problems, mental health, energy/vitality, bodily pain, and general health perception. Two summary scores, the physical (PCS) and mental health component summary, are calculated by the aggregation of the 8 SF-36 subscales, to evaluate the physical and mental health, respectively (higher scores indicating better HRQoL). 9 The effects of dupilumab on the individual ACQ-5 scores (woken at night by asthma, awake in morning with asthma symptoms, limited in activities, shortness of breath, wheezing time), as well as inflammatory biomarkers (eosinophils, eosinophil cationic protein, thymus and activation-regulated chemokine, IgE, and periostin), were also assessed.
Changes in clinical outcomes and PROs from baseline to week 16 in patients with CRSwNP and comorbid asthma were reported as least-squares mean values and analyzed using a mixed-effects model with a repeated-measures approach. An unstructured correlation matrix was used to analyze withinpatient errors; there was no imputation for missing data. A P value <.05 for the comparison between dupilumab and placebo was considered statistically significant.
For each of the individual ACQ-5 scores, a significant difference between treatment groups was observed from baseline to week 16 in favor of dupilumab (Table I) . ACQ-5 responder rate (MCID ! 0.5) was significantly higher (P ¼ .038) in dupilumabtreated patients (62.5%) versus placebo (15.8%). Dupilumab versus placebo produced significant improvements in health status, measured by EQ-5D VAS (P < .001; Figure 1, A) . In dupilumab-treated patients, significant improvements from baseline were observed in 5 SF-36 domains (general health, physical functioning, role-physical, social functioning, and vitality) and PCS (P < .05) (Figure 1, B) . For placebo, change from baseline was statistically significant (P < .05) in only 2 domains (role-physical and social functioning) and PCS (Figure 1,  B) . Dupilumab-treated patients (vs placebo) showed a significantly greater reduction from baseline in serum (P ¼ .002) and nasal (P ¼ .04) secretion levels of total IgE (Table E2 , available in this article's Online Repository at www.jaci-inpractice.org).
This subgroup analysis of patients with CRSwNP and comorbid asthma extends the previously reported observations that adding dupilumab to MFNS treatment improves nasal polyp burden, asthma control, lung function, and HRQoL. 7 The effects of dupilumab on CRSwNP-specific clinical outcomes and PROs in patients with asthma were similar in magnitude to those reported for the overall population. 7 Focusing on PROs, the clinical benefit of dupilumab in patients with CRSwNP and comorbid asthma was observed for CRSwNP disease and symptom severity, and asthma control (assessed by ACQ-5 total and individual item scores) reflecting a reduced impact of asthma on daily activities and an improved HRQoL. Significant FIGURE 1. Change in generic HRQoL outcomes: least-squares mean change from baseline in EQ-5D self-rated health VAS (mm) score at week 16 (A), and in SF-36 individual domain scores at week 16 (B). LS means (and corresponding P values) are based on the mixed-effects model with repeated measures. Blue asterisks indicate statistically significant improvement from baseline within dupilumab-treated patients (P < .05). Gray asterisks indicate statistically significant improvement from baseline within placebo-treated patients (P < .05). BP, Bodily pain; EQ-5D, 5-dimension EuroQoL questionnaire; GH, general health; HRQoL, health-related quality of life; MCS, mental component summary; MFNS, mometasone furoate nasal spray; MH, mental health; PCS, physical component summary; PF, physical functioning; RE, role-emotional; RP, role-physical; SE, standard error; SF, social functioning; SF-36, 36-item Short-Form Health Survey; VAS, visual analog scale; VT, vitality.
improvement from baseline in general health perception, physical functioning, and vitality was only observed with dupilumab treatment and not in the placebo arm.
In conclusion, treatment with dupilumab was associated with an improvement of both clinical and patient-reported NP-specific outcomes, and asthma-specific outcomes in patients with CRSwNP and comorbid asthma. 
